PureTech Health plc

PureTech Health plc is a clinical-stage biotherapeutics company that operates on a "hub-and-spoke" model, dedicated to giving life to science and transforming innovation into value by discovering, developing, and commercializing highly differentiated medicines for devastating diseases. The company's headquarters are located in Boston, Massachusetts, United States.

Through its capital-efficient R&D engine, PureTech Health has generated numerous therapeutic candidates, including three that have received U.S. FDA approval. Its pipeline focuses on immunology, lymphatic, and oncology-based therapeutics, with key programs such as LYT-100 (deupirfenidone) for idiopathic pulmonary fibrosis (IPF) and LYT-200 (an anti-galectin-9 monoclonal antibody) for hematological malignancies and solid tumors. The company's "Founded Entities" model allows it to identify, shape, and de-risk high-conviction assets, scaling them through dedicated structures backed by external capital, with examples including Karuna Pharmaceuticals, Gelesis, Akili Interactive Labs, and more recently, Seaport Therapeutics, Celea Therapeutics, and Gallop Oncology.

Robert Lyne serves as the Chief Executive Officer, having been appointed in December 2025 after an interim period. PureTech Health plc is publicly traded, with its primary listing on the London Stock Exchange under the ticker LSE:PRTC. The company recently announced its intention to voluntarily delist its American Depositary Shares from Nasdaq, effective around May 20, 2026, to streamline governance and focus trading on the LSE. In recent news, PureTech's founded entity, Seaport Therapeutics, priced an upsized Initial Public Offering on Nasdaq in early May 2026, and PureTech reported positive topline data for its LYT-200 program in April 2026.